Ajuts a la recerca

NIH-U19: International collaborations in Infectious Diseases Research

Organisme

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from U.S. institutions and collaborating foreign (non-U.S.) institutions to study infectious diseases (excluding HIV/AIDS) of great public health significance in resource-constrained countries. The collaboration must include, at a minimum, one U.S. institution and one eligible foreign institution. Eligible foreign countries are defined as low-income economies, lower-middle-income economies, and upper-middle-income economies, as defined by the World Bank. This work is expected to increase scientific knowledge on public health related issues, enhance relevant research experience for U.S. and foreign investigators, promote the development of research capacity, and encourage future collaborative relationships. The collaboration must include, at a minimum, one US institution and one eligible foreign institution. However, additional collaborations may be included with other developed countries, and/or with more than one eligible foreign country.

Objecte

Characteristics of the proposed research should include the following:

a. Research on infectious diseases (except HIV/AIDS), including emerging infections, that are of importance and/or interest to the foreign collaborating country, including one or more of the following:

- Research addressing infectious diseases of significant public health importance within the collaborating foreign country that cannot be addressed in the US of other developed countries, such as (but not limited to): dengue, tuberculosis, trachoma, Nipah, and malaria. Research may also include studies of vector-borne pathogens for which the vector is not endemic to the US and/or colonies are not available in US labs.

-Research addressing neglected or understudied infectious diseases where little may be known about the impact on public health in areas outside developed countries, and where there is reason to believe that these infections contribute to the disease burden in the foreign country, including recentrly emerging diseases, such as MERS-CoV.

- Research on infectious diseases in special populations or in the setting of co-infections that are particular to the elegible country/countries. Examples include but are not limited to: pertussis, pneumonia, and diarrhea in infants.

-For diseases that can be studied within US populations, research must focus on aspects of disease or on populations that are not available in the US. Examples include but are not limited to: vector-pathogen-reservoir interactions, regional epidemiology, Chagas disease, congenital syphilis, influenza in tropical areas and hepatitis. Also included are emerging and unique diseases that are rare in the US, such as those caused by the viral hemorrhagic fever viruses.

b. Research may focus on more than one organism/infectious disease (e.g. diarrheal or respiratory diseases), including co-infections and microbiome studies, provided a strong rationale is given.

c. Studies may be proposed on any aspect of infectious diseases, including, but not limited to: the epidemiology, natural history of disease, pathogenesis, and immunopathogenesis, epidemiologic or natural history studies to define the incidence, clinical presentations, time course, and outcomes of diseases, studies of correlates of immunity to infectious diseases in patients with little or no disease; identification of resistance patterns, identifications of biomarkers taht can be used to develop diagnostics, targets for therapy or vaccines; characterization of susceptible cohorts for a particular pathogen; and pilot or feasibility studies in preparation for larger studies.

d. Development and/or evaluation of point-of-care or improved diagnostics is encouraged. Evaluation of new diagnostics is allowed as long treatment/care is determined by standard, accepted procedures and results of the evaluated diagnostic for an individual are not reported back to the treating physician and do not impact care. Routine diagnosis, treatment, and care must be provided outside of the proposed research project.

e. Development of immunological, microbiological, biostatistical, epidemiological, data management and clinical research capacity at the endemic sites is trongly encouraged. Multidisciplinary collaborations are encourages to ensure the appropiate breadth of scientific expertise in contributing fields, in contributing fields, including but not limited to infectious diseases, biochemistry, immunology, genetics, pharmacology, molecular biology, microbiology, zoology, medical entomology.

Termini oficial

1. Letter of Intent: Official deadline: February 7th, 2014.

2. Full appplication: Official deadline: March 7th, 2014.
Termini IISPV

Termini IISPV

1- Declaration of interest: IISPV's deadline: January 15th, 2014 (europa@iispv.cat)

2- NIH Register; create PI account(s); affiliate PI account to IISPV, etc.

3- Letter of Intent: IISPV's deadline: January 31st, 2014

4. Full proposal: IISPV's deadline: March 1st, 2014.

Pujar